Invalidity dossier
US 9879052
Added 9/20/2026, 5:22:02 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US 9,879,052 B2
Title: Integrin-blocking polypeptides and uses thereof
Patent number: US 9,879,052 B2 (application US 15/245,487; publication US 2017/0051018 A1)
Inventors: Hanmei Xu, Chunyan Pu, Zhian Kang
Assignee: Listed as "Individual" (original and current assignee; the source notes listed assignees may be inaccurate). Assignment records name Hanmei Xu, with Zhian Kang and Chunyan Pu as assignors.
Key dates: Priority date 2011-12-27, claimed from CN 201110443052.2 (CN 102850443 B); filing date 2016-08-24; publication date 2018-01-30; anticipated expiration 2032-12-26. Legal status listed as Active.
Purpose: The patent relates to the pharmaceutical field, specifically a series of integrin blockers described as having strong angiogenesis-inhibiting performance, high integrin affinity, and integrin-binding capacity. The polypeptides are said to be usable in treating solid tumors and rheumatoid arthritis (RA).
Plain-language scope: The disclosed polypeptides contain two functional sequence elements: an integrin ligand sequence including Arg-Gly-Asp (RGD) plus Gly-Gly-Gly-Gly-Ala-Cys-Arg-Gly-Asp-Cys-Phe-Cys (SEQ ID NO: 6), and an angiogenesis-inhibiting sequence (SEQ ID NO: 7). Two polypeptides are specifically named: polypeptide II (SEQ ID NO: 2) and polypeptide III. The RGD element is said to target integrins—particularly αvβ3—while the second element inhibits angiogenesis, thereby slowing tumor growth and metastasis. The text also describes use against RA by inhibiting synovial angiogenesis and pannus formation. A generic sequence is recited beginning "X-Phe-Gln-Pro-Val-Leu-His-Leu-Val-Ala-Leu-Asn-Ser-Pro-Leu-Ser-Gly-Gly-Met-Arg-Gly-Ile-Arg-Gly-Ala-Asp-Phe-Gln-Cys-Phe-Gln-Gln-Al…" (excerpt truncated).
What the excerpt does not establish: It does not establish claims, claim scope, experimental data, dosing, or clinical efficacy; the sequence list is incomplete. No litigation, ownership-transfer, validity, or prior-art analysis is presented here.
Generated 10/1/2026, 10:02:44 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 9879052. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.